Tracking and Translating the Field

Bridging the scientific field and communities where research happens

We track and translate complex science, funding and policy decisions, community advocacy and more, to make it accessible, give context, identify gaps and opportunities for advocacy and ensure community priorities are at the center of global health. 

HIV prevention research and development is accelerating, with more options available than ever before. But progress toward crucial targets to end the epidemic and prepare for future ones has been far too slow. New leadership, research, and commitments at the global, national, and local levels bring power and potential to strengthen and advance HIV prevention and global health equity, however, but we need to ensure that new policies and product access initiatives are inclusive and donors and decision makers are accountable. 

AVAC tracks important issues, in research, policy, financing, news headlines and more. With colleagues and partners, we analyze the data, issues, policy and perspectives, and we translate it into useful and usable resources that all can use to inform their work. We do this by: 

  • developing and sharing communications, reports and materials that provide accessible, up-to-date resources on the full spectrum of biomedical HIV prevention products from research to rollout and real-time analysis of emerging developments; 
  • keeping pace with and widely sharing information on emerging developments in the field of HIV prevention research through various databases and accessible online platforms; 
  • promoting informed decision making, evidence-based advocacy and awareness raising around timely issues in HIV prevention research and product development, as well as integration with other related areas of health; and
  • convening conversations, meetings, and workshops with various stakeholders to share complex science to ensure that communities, advocates, and decision makers have clear, accurate, equitable, and timely access to information to strengthen evidence-based advocacy, policies, and programs.

Upcoming Events & Webinars

African Workshop on HIV & Women 2025

Meeting

Read More

Conference on Retroviruses and Opportunistic Infections 2025

Meeting

Read More

What's New

report

PxWire Volume 15, Issue 2

The field of HIV prevention is confronted with two opposing forces—programs for delivering PrEP have been shuttered all over the world by the withdrawal of the US government from global health while next-generation long-acting products have never held greater promise to accelerate HIV prevention and help the world achieve epidemic control. This issue provides a snapshot on threats to delivering PrEP, the potential of injectable lenacapavir (LEN) for PrEP, and on the implications of upstream research and development of other long-acting PrEP.

HIV
Read more

infographic

An "Innovation Pile-Up" in Next-Generation LA-PrEP is Possible

The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028. Markets and policies must be built to support the products in the market already, so that new options can be rapidly deployed and deliver impact. Otherwise, the field will squander time and money, with epidemic control slipping further out of reach.

HIV
Read more

The Future of ARV-Based Prevention and More

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of MPTs in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.

Use this infographic:

Embed Download PDF Download Image
See more infographics

Related Projects

The Latest on Tracking and Translating the Field

Article

Global Health Watch: WHA78, Misinformation at Congressional Hearings, Global Fund Cuts & More

The US Secretary of State and the Secretary of Health and Human Services appeared before Congress this week defending foreign aid cuts and the dismantling of USAID. Advocates are responding, including the Treatment Action Group (TAG) which issued a stark warning: US agencies are engaging in “unethical, dishonorable, and potentially law-breaking machinations” under new leadership, particularly at the NIH. Meanwhile, the US was absent from the World Health Assembly, where the WHO Pandemic Agreement was ratified and where a high-level dialogue on long-acting HIV prevention took place. All this plus looming Global Fund shortfalls, and new COVID-19 vaccine policy changes in this week’s issue.

Event

100 Days In: How HIV Advocates are Meeting the Moment

In its first 100 days, the Trump administration proposed deep cuts to public health and HIV funding, attacked evidence-based healthcare, defunded scientific research, rolled back protections for LGBTQ+ people, and emphasized punitive criminal legal approaches. These moves pose serious threats to the future of HIV-related services, care, prevention, and the broader struggle for health equity and racial justice in our multiracial democracy.

Join CHLP for this moderated panel discussion focused on what the first 100 days of the Trump administration have meant for our communities, particularly people living with HIV, Black and brown people, LGBTQ+ people, and those impacted by criminalization, and how we are collectively shifting strategy to meet the current political moment.

Presentation

HIV Prevention R&D at Risk

AVAC’s analysis of the impact of US Government funding cuts, terminated projects, and other policy changes on the HIV prevention research and development (R&D) pipeline, and on HIV research broadly.